100results about How to "Reducing treatment" patented technology

The present invention relates to a pulverulent polymer post-crosslinked on the surface and absorbing water or aqueous liquids, synthesised from polymerised, optionally pre-crosslinked monomers containing partially neutralised carboxyl groups. The present invention also relates to a process for the post-treatment of the aforementioned polymers and the use of a solution of at least one salt of an at least trivalent cation for restoring the gel permeability of the aforementioned polymers that have been damaged by mechanical action.

The present invention provides a method of treating a prostate in a patient in need thereof and a heating catheter, or an electromagnetic radiation applicator, system suitable for effecting the present inventive method. The present inventive method provides for substantial unexpected improvement in patient outcome by providing, inter alia, a preferred therapeutic temperature for thermotherapy of the prostate and a method of decreasing a patient's intolerance due to pain. The present inventive system provides for, inter alia, automatic implementation of the present inventive method.

The invention relates to a method and apparatus for predicting a sudden heart abnormality for an individual patient. In order to provide a prediction mechanism that is suitable for acute care, three sub-indices are determined based on medical data obtained from the patient. The first sub-index indicates the level of deterministic chaos in the heart rate variability of the patient, the second sub-index indicates the energy level in the myocardium of the patient, and the third sub-index indicates the degree of ventricular arrhythmia of the patient. Based on the first, second, and third sub-indices, at least one overall risk index is then determined, the overall risk index indicating the risk level of a sudden heart abnormality for the patient.

In one embodiment, the present invention provides a method of reducing the viscosity of a viscosified treatment fluid comprising contacting the viscosified treatment fluid with an acid generated from an orthoester composition that comprises an orthoester. In another embodiment, the present invention provides a method of reducing the pH of a viscosified treatment fluid comprising providing an orthoester composition that comprises an orthoester; contacting the viscosified treatment fluid with the orthoester composition; allowing the orthoester to generate a generated acid; and allowing the generated acid to at least partially reduce the pH of the viscosified treatment fluid. Embodiments of fracturing and gravel packing methods also are disclosed.

A connecting means adapted to fix or release a first element (4) and a second element (5) includes a locking pin (1) which is moveable to remote activation means between a locked position. In which leg (8) expends wall (9) into recess (10), and an unlocked position. The remote activation means may be magnetic, electro-magnetic or any other suitable means. A method of fixing or releasing first and second elements by remote activation means is also disclosed. The invention further provides a first element having first means (166) adapted to cooperate with second means (165) on a second element to facilitate connection of the first and second elements. A method of manufacturing the first element includes the steps of depositing discrete amounts of setable material on a surface of the first element and inverting the element to permit the material to set under the influence of gravity. A method of reducing the spacing between first and second elements by remote activation means is also disclosed.

An oxygen reducing electrode for a fuel cell comprises carbon particles as support for catalyst particles. The carbon particles are coated with smaller particles of a metal oxide and/or metal phosphate (for example, TiO₂ particles) to impede destructive oxidation (corrosion) of the carbon particles while permitting suitable electrical conductivity between the carbon particles. The catalyst is carried on the smaller particle-coated carbon particles. Titanium dioxide particles can be dispersed on carbon particles suspended in a liquid medium by ultrasonic decomposition of a suitable titanium precursor compound.

Disclosed are compositions and methods for the treatment and/or prevention of rheumatoid arthritis, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.

Embodiments disclosed herein provide predictive analysis of medical treatment pathways to assist healthcare providers and/or patients determine the statistical probability of a treatment outcome, among the experience of a large patient and provider population, of a particular treatment step along a defined treatment pathway for a specific patient of interest. Specifically, a plurality of predictive models, based on data from a large and demographically similar patient population, are created for a plurality of treatment paths stemming from a selected treatment node within a medical treatment pathway of a clinical guideline. Medical data for the patient of interest is input to the plurality of predictive models, and model generated treatment outcome probabilities for the patient of interest are generated and compared for each of the plurality of treatment paths stemming from the selected treatment node.

A bracket for orthodontic use has a base plate, a tie wing and an arch wire fitting slot. More specifically, a pair of tie wings having a pair of long and short wing pieces, i.e., a long piece and a short piece, are erected on the rectangular base plate and spaced apart, and the arch wire fitting slot is formed by the spaced apart portion. A pair of wing pieces of the tie wing are provided to project in the vertical direction with distal ends directed downward, and constituted the wing pieces include a long piece and a short piece. A recessed guide groove is provided in a vicinity of an end of the long piece.

The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.

A composition comprises plasmin or an enzymatically equivalent derivative thereof and at least an anti-inflammatory medicament. The composition can be used to effect or induce a controlled posterior vitreous detachment (“PVD”) to prevent, treat, or ameliorate a potential complication of a pathological ocular condition. Such a composition can be administered intravitreally.

A method and apparatus for the treatment of bottles or similar containers. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

The present invention relates to methods of inhibiting native and promiscuous uptake of biogenic amine neurotransmitters with triple reuptake inhibitors in the treatment of conditions affected by monoamine neurotransmitters.

The present invention discloses a process for preparing a water-dispersible photosensitive composition, including the steps of: (a) adding an unsaturated photomonomer and/or a plasticizer to a carboxyl-group bearing acrylic resin solution which contains at least an organic solvent; (b) distilling and removing said organic solvent to form a resin paste; (c) dissolving a photoinitiator and an alkaline into said resin paste; (d: adding deionized water and mixing thoroughly to form an emulsion; and (e) adjusting the viscosity or said emulsion with a water-soluble resin.

The present invention provides a process for efficiently preparing a light transmissive electromagnetic wave shielding material enhanced in light transmissive property, electromagnetic wave shielding property, appearance and legibility, and having high-accuracy mesh-pattern. The process for the preparation of a light transmissive electromagnetic wave shielding material comprising; printing in the form of mesh a pretreatment agent for electroless plating on a transparent substrate to form a mesh-shaped pretreatment layer, the pretreatment agent comprising a fine particle having an extremely-thin film of noble metal on its surface, and subjecting the mesh-shaped pretreatment layer to electroless plating to form a mesh-shaped metal conductive layer on the pretreatment layer.

An ester formed from an inositol or an inositol derivative and niacin, wherein the inositol or the inositol derivatives comprises a stereoisomer selected from allo-inositol, cis-inositol, epi-inositol, muco-inositol, neo-inositol, scyllo-inositol, D-chiro-inositol and L-chiro-inositol, or pharmaceutically acceptable salts thereof. Examples of esters include inositol hexaniacinates such as allo-inositol hexaniacinate and cis-inositol hexaniacinate. The esters can be used to treat any disorder that is treatable with niacin therapy such as dyslipidemia, hypercholesterolemia, hyperlipidemia or cardiovascular disease. The esters can be administered with other agents such as HMG-CoA reductase inhibitors, statins, fibrates, activators of peroxisome proliferator activated receptors poli-cosanol, phytosterols, tocotrienols, calcium, bile acid sequestrants, guar gum and free niacin. The invention includes pharmaceutical compositions containing these compounds.

In a micronanobubble reaction vessel 3 of wastewater treatment equipment, wastewater containing organic matter is treated with micronanobubbles. Thereafter, the 5 wastewater is introduced into an aeration tank 7. Part of organic matter in the wastewater is oxidized in the micronanobubble reaction vessel 3 by micronanobubble treatment prior to treatment with activity of microorganisms enhanced in the aeration tank 7. After organic matter load is thus reduced, the treatment water is introduced into the aeration tank 7, in which microorganisms exist in high concentration due to submerged membranes 17, so that the organic matter in wastewater can be effectively treated. This makes it possible to accomplish miniaturization of the aeration tank 7, reduction in scale of the whole equipment and therefore reduction in initial cost. Also, a photocatalyst tank 22 is provided downstream of the aeration tank 7, so that a minute amount of organic matter unaffected by the microbial treatment alone can be oxidized at high-level by using a photocatalyst plate 24.